Bozhanova, Nina G. http://orcid.org/0000-0002-2164-5698
Flyak, Andrew I.
Brown, Benjamin P.
Ruiz, Stormy E. http://orcid.org/0000-0003-0892-9626
Salas, Jordan
Rho, Semi
Bombardi, Robin G.
Myers, Luke http://orcid.org/0000-0003-1132-2550
Soto, Cinque
Bailey, Justin R.
Crowe, James E. Jr. http://orcid.org/0000-0002-0049-1079
Bjorkman, Pamela J. http://orcid.org/0000-0002-2277-3990
Meiler, Jens http://orcid.org/0000-0001-8945-193X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI127469, U01 AI150739, R01 AI141661, U19 AI159822, K99 AI153465, K99 AI153465, R01 AI127469, U01 AI150739, R01 AI141661, R01 AI127469, U19 AI159822, U01 AI150739, R01 AI141661)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (P41GM103393)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 22 March 2021
Accepted: 20 May 2022
First Online: 8 June 2022
Competing interests
: J.E.C. has served as a consultant for Luna Innovations, Merck, and GlaxoSmithKline, is a member of the Scientific Advisory Board of Meissa Vaccines, and is the Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from Takeda Pharmaceuticals, IDBiologics and AstraZeneca. Some human monoclonal antibodies in this paper are described in International Patent Application No. PCT/US2018/029315 entitled “Broadly Neutralizing Antibodies Against Hepatitis C Virus”, filed by Vanderbilt University on behalf of Vanderbilt and Johns Hopkins University; JEC, AIF and JRB are listed as inventors. The remaining authors declare no competing interests.